Anti Amyloid Leqembi denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Leqembi as Non-Formulary — and Why You Can Appeal

Leqembi (lecanemab) is a specialty biologic administered by infusion and may not appear on UHC's standard formulary for a given plan, or may be placed on a tier requiring prior authorization before formulary exception consideration. A non-formulary denial does not mean the drug is unavailable — it means a formulary exception process must be completed. For a drug with FDA approval and no therapeutically equivalent alternative, formulary exception requests are regularly granted.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, non-formulary denials are subject to the same internal appeal and external review rights as any other denial. Additionally, many plans are required to grant a formulary exception when no formulary alternative is clinically appropriate. You have up to 180 days from the denial notice to file internally, and the external review window is approximately four months from exhaustion of internal remedies. Expedited review is available when delay creates urgent clinical risk.

## What to Gather

• No-equivalent-alternative documentation: The prescriber must state in writing that no formulary-listed alternative addresses the same therapeutic target (amyloid pathology) as lecanemab, because no other approved anti-amyloid therapy is interchangeable for this patient's confirmed indication.
• Diagnosis and amyloid confirmation: PET or CSF amyloid-positive results, cognitive staging, and a confirmed early Alzheimer's disease diagnosis.
• Medical-necessity letter: A letter from the treating neurologist explaining why lecanemab specifically is required and why any formulary alternative (if one exists) is clinically inadequate or inappropriate for this patient.
• Prior treatment history: Documentation of any prior therapies tried and their outcomes.
• UHC formulary exception request: Confirm whether a formal exception request was submitted alongside the PA; if not, submit one now as part of the appeal.

## Criteria-Mapping Approach

Request UHC's formulary exception criteria in writing. Identify each requirement — typically: (1) a formulary alternative exists and is clinically inappropriate, or (2) no formulary alternative exists for the condition. For lecanemab, the argument most often turns on the absence of a therapeutically equivalent formulary option for amyloid-targeting therapy. Build the appeal letter around that structural gap, supported by the prescriber's clinical explanation and the FDA label's approved indication.